Navigation Links
Epigenetic control of cardiogenesis
Date:1/29/2013

This press release is available in German.

Many different tissues and organs form from pluripotent stem cells during embryonic development. To date it had been known that these processes are controlled by transcription factors for specific tissues. Scientists from the Max Planck Institute for Molecular Genetics in Berlin, in collaboration with colleagues at MIT and the Broad Institute in Boston, have now been able to demonstrate that RNA molecules, which do not act as templates for protein synthesis, participate in these processes as well. The scientists knocked down a gene for long non-coding RNA molecules (lncRNA) and thereby disrupted the development of the heart to an extent that was lethal to the embryos. Genesis of the ventral body wall was also impaired. It became apparent that the lncRNA participates in controlling transcription factors that themselves are responsible for controlling tissue- and organogenesis. The lncRNA itself thus acts as a modulating factor in these processes.

RNA molecules more than 300 nucleotides long and not exhibiting any protein-coding read frames are denoted as long non-coding RNA. They are known to interact with histone-modifying protein complexes that control the activation state of genes (activatable, active, or repressed), as well as influencing the level of their activity. This occurs, for example, through the transfer of methyl groups to histones, the DNA-packaging proteins. Modifications to the histones such as these can be copied during cell division and thus promulgate the activation state of genes from cell to cell across several stages of differentiation.

Max Planck scientists led by Bernhard Herrmann have proven for the first time that lncRNAs may also be indispensable for embryonic development. This was previously known primarily for transcription factors. They discovered an lncRNA, termed Fendrr, which is specifically formed in the progenitor cells of the heart and ventral body wall. After knocking down Fendrr in a mouse, the heart and ventral body wall were malformed, which was lethal to the embryos. The malformations first arose, however, several days after Fendrr had already been knocked down in the progenitor cells. In the case of transcription factors, the malformations appear, in contrast, after their inactivation for cells in which the gene is normally active.

This delay between the expression of the Fendrr-RNA and the appearance of the malformation can be explained by the specific effect of this new class of regulators. They influence the epigenetic control of target genes, including important transcription factors, namely by binding to histone-modifying protein complexes. Thus, they influence the fate of the descendants of cells in which they themselves were only briefly active.

The scientists now hope to locate further lncRNAs that control cardiogenesis and additional processes of embryonic development in mammals, and shed light on the mechanism of how they operate. Fendrr is probably only one of many lncRNAs that participate in epigenetic control of regulators for tissue- and organogenesis.


'/>"/>

Contact: Bernhard G. Herrmann
herrmann@molgen.mpg.de
49-308-413-1409
Max-Planck-Gesellschaft
Source:Eurekalert  

Related medicine news :

1. Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
2. Epigenetics emerges powerfully as a clinical tool
3. New evidence for epigenetic effects of diet on healthy aging
4. Personal epigenetic signatures found consistent in prostate cancer patients metastases
5. Depo-Provera Birth Control Might Raise Breast Cancer Risk
6. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
7. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
8. How the brains daily clock controls mood: A new project
9. Guidelines say diet, exercise, weight control improve odds after cancer diagnosis
10. Control of gene expression: Histone occupancy in your genome
11. MSU plan would control deadly tsetse fly
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Epigenetic control of cardiogenesis
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... OR (PRWEB) , ... April 28, 2017 , ... ... http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here ... Power of Water, Global Climate Change and Your Health on Voice America sponsored ...
(Date:4/28/2017)... , ... April 28, 2017 , ... The Texas Cord ... recently to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg ... give birth at the hospital and decide to donate. , “Women’s Hospital at ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... Creator responds to and which He does not. Yisrayl says with so many titles ... the true name, but he says with a little Scripture, backed with a lot of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: